The mTOR inhibitor enhances chemosensitivity of androgen-independent prostate cancer cell line.
- Author:
Jin-Sheng XIA
1
;
Xian-Guo CHEN
;
Qian-Yuan ZHUANG
;
Ji-Hong LIU
;
Zhang-Qun YE
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; pharmacology; Cell Cycle; drug effects; Cell Line, Tumor; Drug Therapy, Combination; Humans; Male; Paclitaxel; pharmacology; Prostatic Neoplasms; drug therapy; Protein Kinase Inhibitors; pharmacology; Sirolimus; analogs & derivatives; antagonists & inhibitors; pharmacology
- From: National Journal of Andrology 2009;15(7):617-620
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect of the mammalian target of rapamycin (mTOR) inhibitor CCI-779 on the chemosensitivity of androgen-independent prostate cancer cell line PC-3.
METHODSProstate cancer cells PC-3 were cultured and treated with CCI-779, Paclitaxel and combination of the two. Then the inhibitory effects of the three medications on the growth of the PC-3 cells were determined by MTT, and the their cell cycle and apoptosis were detected by flow cytometry.
RESULTSCompared with the control group, the three medications all significantly inhibited the proliferation of the PC-3 cells, and the combined method even enhanced the effect. Flow cytometry showed that CCI-779 and Paclitaxel blocked the cell cycle mainly in the G1/G2 stage, while the combined medication mainly in the G0/G1 stage. Significantly increased apoptosis of the PC-3 cells was observed in the three medication groups as compared with the control group (P < 0.01).
CONCLUSIONCCI-779 can inhibit the proliferation of PC-3 cells and enhance the chemosensitivity of prostate cancer.
